Story
Argenx Upgraded to Buy by UBS on $20 Billion Peak Sales Outlook for Vyvgart

UBS has upgraded Argenx (EBR:ARGX) to a 'Buy' rating and substantially increased its price target, citing a clearer path for the biopharmaceutical company's flagship drug, Vyvgart, to reach nearly $20 billion in peak sales.
Following the analyst action, shares of Argenx rose 2.8% in Brussels trading, as reported by Investing.com.
Analyst Lifts Rating and Target
In a note to clients on Wednesday, UBS raised its rating on Argenx to 'Buy' from 'Neutral' and lifted its price target to $1,400 from a previous $960. Analyst Xian Deng attributed the upgrade to better-than-expected clinical data for Vyvgart and an "underappreciated" pipeline beyond the company's lead asset.
The bank's valuation model, which uses a blend of discounted cash flow analysis and peer multiples, suggests that higher projected sales and pipeline contributions will more than compensate for increased near-term spending on selling, general, and administrative expenses.
Vyvgart's Growth Trajectory
The core of the bullish thesis is the massive commercial potential for Vyvgart. UBS raised its probability-adjusted peak sales forecast for the drug to $18 billion, a figure approximately 15% above the market consensus.
AdThis optimism is largely driven by recent developments:
- Myositis Data: Following strong Phase 3 results, UBS now models $5.5 billion in adjusted peak sales for myositis subtypes, more than double the consensus estimate of $2.6 billion. The bank noted a larger addressable patient population and fewer alternative treatments for the condition.
- Future Indications: The note also expressed bullishness on Vyvgart’s ongoing Phase 3 trial in Sjogren’s disease, with results anticipated in the second half of 2027.
Diversifying Beyond a Single Product
UBS also highlighted Argenx's progress in addressing investor concerns about its reliance on a single product. The analyst expressed "high conviction" in the Phase 3 readout for empasiprubart in multifocal motor neuropathy (MMN), expected in the fourth quarter of 2026.
A successful trial would mark the first launch of a non-Vyvgart drug for Argenx, a key diversification milestone. The report also pointed to the company's recent $2 billion acquisition of Forte, which added an early-stage drug for rare diseases like vitiligo, as another step toward broadening its pipeline.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.